Dai ichi Life Insurance Company Ltd Sells 2,383 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dai ichi Life Insurance Company Ltd reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 12,392 shares of the biopharmaceutical company’s stock after selling 2,383 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,027,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. International Assets Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Swedbank AB purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $129,257,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after acquiring an additional 96,266 shares during the last quarter. TD Asset Management Inc raised its position in Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $749.51 on Tuesday. The company has a market cap of $82.36 billion, a P/E ratio of 18.55, a PEG ratio of 2.84 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average price is $937.00 and its 200 day moving average price is $1,025.99.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent research reports. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.